There are also side effects from rapid weight loss on the skin and body shape
To maintain health benefits and avoid rapid weight regain, research shows many people will need to stay on these drugs long-term
The negative attitude of Novo Nordisk was summed up by Lars Srenson, the company's CEO, who in 2005 argued 'Obesity is primarily a social and cultural problem
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has a slightly different receptor activity profile and may be tolerated differently, though gastrointestinal side effects remain common
Additionally, weight regain often plateaus at around 75.6% of the weight lost, leaving only 40.2% of the initial weight loss intact after one year
Modeling the blood-brain barrier: beyond the endothelial cells